top of page

Tackling the Serious Global Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases

LEARN MORE
Appili Therapeutics Infectiou Disease Drug Development Program

Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.

Leadership team skilled in advancing programs with upside potential

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives

LATEST NEWS RELEASES

Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
Read More
03/20/2023
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
Read More
02/14/2023
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
Read More
2/08/2023
Company Conference Room

LATEST EVENTS

Appili Therapeutics Announces Additional Funding of CAD$2.5 million under Non-Convertible Secured Loan with Long Zone Holdings
Read More
03/20/2023
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
Read More
02/14/2023
Appili Therapeutics Announces that FDA accepts the ATI-1501 NDA
Read More
2/08/2023
bottom of page